Zambon finally launches Xadago (safinamide) in the United Kingdom as a treatment for idiopathic Parkinson's disease.

Zambon and its partner Newron Pharmaceuticals have now launched Xadago (safinamide) in the United Kingdom, more than a year after it was approved by European regulators and following launches in Germany, Switzerland, Spain, Italy, Belgium, Denmark, and Sweden.

Xadago is a once-daily therapy for idiopathic Parkinson's' disease, offering a unique mode of action including selective and reversible MAO-B-inhibition and blocking of voltage dependent sodium channels, which leads to modulation of abnormal glutamate release. Clinical trials have demonstrated its efficacy in controlling motor symptoms and motor complications in the short term, with data supporting this effect over two years.

The drug is indicated for the treatment of adults with idiopathic PD as an add-on therapy to a stable dose of the gold standard Levodopa (L-dopa), alone or in combination with other PD medicines, in mid-to late-stage fluctuating patients.